JavaScript is off. Please enable to view full site.

No safety concerns yet in trials of GSK's Ebola vaccine

Monday, November 17, 2014, 18:42 GMT+7

Almost 200 people have received GlaxoSmithKline's experimental Ebola vaccine in trials in the United States, Britain, Mali and Switzerland, and the safety data so far are "very satisfactory", scientists said on Monday.

>> WHO starts survey of Ebola treatments, says none proven so far

The trials, which began just over two months ago, have been using healthy volunteers, rather than patients with Ebola, to test whether the vaccine is safe for humans.

The experimental shot uses a single Ebola virus gene from a chimpanzee virus to generate an immune response. Because it doesn't contain any infectious virus material, it can't infect those being vaccinated.

Adrian Hill, a professor at Oxford University who is leading the British arm of the trial, said 20 people at the U.S. National Institutes of Health in Bethesda, Maryland, 80 people at the University of Maryland School of Medicine Center for Vaccine Development in Mali, 34 people out of an eventual 120 at the University Hospital of Lausanne, and 59 out of an eventual 60 at the University of Oxford had so far been given the shot.

"The safety data here have looked very satisfactory so far," Hill said in a statement. "The response we have seen from people coming forward to take part has been remarkable."

The West Africa Ebola epidemic has now infected more than 13,000 people -- mainly in Guinea, Sierra Leone and Liberia -- and killed more than 5,000 of them, according to the World Health Organization (WHO).

Several drug companies are now accelerating Ebola vaccine trials and the WHO has said it hopes one or more of the vaccines may be ready for some limited use in West Africa in early 2015.

GSK's vaccine and another leading candidate made by NewLink Genetics are already in human trials. Five more should begin testing in the first quarter of next year, according to the WHO. One from Johnson & Johnson will start trials in January.

Hill said the teams running the GSK vaccine trial should know by late December 2014 how the immune responses of Malian health care workers who have had the shot compare to those observed in adults given the vaccine in Britain and Switzerland.

Like us on Facebook or follow us on Twitter to get the latest news about Vietnam!



Read more




Vietnam’s Mekong Delta celebrates spring with ‘hat boi’ performances

The art form is so popular that it attracts people from all ages in the Mekong Delta

Vietnamese youngster travels back in time with clay miniatures

Each work is a scene caught by Dung and kept in his memories through his journeys across Vietnam

Experience summer sand-boarding in Mui Ne

Sand-boarding, a popular activity amongst local children in the coastal tourism town of Mui Ne in south-central Vietnam, is attracting hundreds of tourists to the Red Sand Dunes

Young maple trees given better protection as Hanoi enters rainy season

The trees are currently growing well, with green leaves and healthy branches.

Hunting skinks for food in southern Vietnam

Skink meat is known to be soft, tasty, and highly nutritious.

Latest news